UNSPSC 51411700: Vasodilator alkaloids

Vasodilator drugs made from organic nitrogenous bases.

UNSPSC 51411700 Vasodilator alkaloids is a Class code under which state and local governments procure emergency medical and hospital medications, particularly advanced life support drugs used by fire rescue departments, health agencies, and cooperative purchasing networks serving multiple jurisdictions. Recent solicitations show purchasing bodies acquiring specific vasodilator and cardiac medications—epinephrine, diltiazem, adenosine, and labetalol—in quantities ranging from hundreds to thousands of units per contract. Issuing bodies include city purchasing departments (Tampa Fire Rescue through the City of Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The work involves supply of FDA-compliant pharmaceutical products with tight expiration-date management (nine months or more from acceptance), delivery within days to weeks, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and provision of Safety Data Sheets and accessibility documentation.

Geographic activity centers on Florida, Texas, and Minnesota with spillover to Oregon via the MMCAP cooperative vehicle. Representative recent opportunities include the City of Tampa's IFB for Advanced Life Support Medications (Bid No. 26-P-00188, posted April 24, 2026, due April 8, 2026) seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with an estimated contract value of $40,000 and a five percent bid discount for Small Local Business Enterprise participation; the Minnesota MMCAP RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802, due March 26, 2026) establishing multi-award manufacturer contracts effective July 1, 2026 with 75 percent weight on price competitiveness; and the Texas HHS Commission's RFI for Direct-to-Manufacturer Prescriptions (HHS0017013, April 3, 2026) exploring direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. Contract terms typically range from one to two years with renewal options.